216 related articles for article (PubMed ID: 34224737)
1. A single homogeneous assay for simultaneous measurement of bispecific antibody target binding.
Christian EA; Hussmann GP; Babu M; Prophet M; Mazor Y; Chen W; Grigoriadou C; Lin S
J Immunol Methods; 2021 Sep; 496():113099. PubMed ID: 34224737
[TBL] [Abstract][Full Text] [Related]
2. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of semi-homogeneous assay formats for dual-specificity antibodies.
Jiang G; Lee CW; Wong PY; Gazzano-Santoro H
J Immunol Methods; 2013 Jan; 387(1-2):51-6. PubMed ID: 23063556
[TBL] [Abstract][Full Text] [Related]
5. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies.
Parker CL; Jacobs TM; Huckaby JT; Harit D; Lai SK
mBio; 2020 Jan; 11(1):. PubMed ID: 31964730
[TBL] [Abstract][Full Text] [Related]
6. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
7. Dual-target Bridging ELISA for Bispecific Antibodies.
Pei M; Wang Y; Tang L; Wu W; Wang C; Chen YL
Bio Protoc; 2022 Oct; 12(19):. PubMed ID: 36313202
[TBL] [Abstract][Full Text] [Related]
8. Di-diabody: a novel tetravalent bispecific antibody molecule by design.
Lu D; Jimenez X; Zhang H; Atkins A; Brennan L; Balderes P; Bohlen P; Witte L; Zhu Z
J Immunol Methods; 2003 Aug; 279(1-2):219-32. PubMed ID: 12969563
[TBL] [Abstract][Full Text] [Related]
9. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
10. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
[TBL] [Abstract][Full Text] [Related]
11. The comparison of the ability of monoclonal antibodies directed to different proteins (human IgG, human myoglobin and HRP) and bispecific antibodies derived thereof to bind antigens immobilized on a surface of a solid phase.
Dmitriev DA; Massino YS; Segal OL; Smirnova MB; Kolyaskina GI; Pavlova EV; Osipov AP; Egorov AM; Dmitriev AD
Clin Chim Acta; 2001 Jul; 309(1):57-71. PubMed ID: 11408007
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
13. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
14. "Two-in-One" approach for bioassay selection for dual specificity antibodies.
Lee HY; Schaefer G; Lesaca I; Lee CV; Wong PY; Jiang G
J Immunol Methods; 2017 Sep; 448():74-79. PubMed ID: 28579366
[TBL] [Abstract][Full Text] [Related]
15. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
16. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
17. Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen.
Yumura K; Akiba H; Nagatoishi S; Kusano-Arai O; Iwanari H; Hamakubo T; Tsumoto K
J Biochem; 2017 Sep; 162(3):203-210. PubMed ID: 28637250
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies: a mechanistic review of the pipeline.
Labrijn AF; Janmaat ML; Reichert JM; Parren PWHI
Nat Rev Drug Discov; 2019 Aug; 18(8):585-608. PubMed ID: 31175342
[TBL] [Abstract][Full Text] [Related]
20. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
Li H; Er Saw P; Song E
Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
